SCHEMBL4635923

SCHEMBL4635923

CS(=O)(=O)Nc1ccc(C(=O)N2CC3C(N)C3C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 3/20 0.47
CRHR2 Q13324 3/20 0.47
KMT2A Q03164 3/20 0.46
HPGD P15428 1/20 0.43
RECQL P46063 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
BCL2 P10415 2/20 0.43
BECN1 Q14457 2/20 0.43
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
NAMPT P43490 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635251 0.82 CRHBP (0.71) CRHBPCRHR2KMT2AHPGDRAB9A
SCHEMBL23775472 0.81 CRHBP (0.51) CRHBPCRHR2KMT2AADRB2ADRB1
SCHEMBL10417608 0.81 ADRB2 (0.58) KMT2AHPGDRECQLADRB2ADRB1
SCHEMBL4636528 0.80 TSHR (0.54) KMT2AHPGDMEN1ALDH1A1HTT
SCHEMBL4635095 0.80 KMT2A (0.70) CRHBPCRHR2KMT2ARAB9ANPC1
SCHEMBL28086313 0.78 NPC1 (0.64) KMT2AHPGDRAB9ANPC1MEN1
SCHEMBL4635076 0.77 HSD11B1 (0.46) KMT2AHPGDNPC1MEN1ALDH1A1
SCHEMBL4636574 0.77 PKM (0.56) CRHBPCRHR2KMT2AHPGDMEN1
SCHEMBL9864972 0.77 NPC1 (0.67) KMT2AHPGDRAB9ANPC1MEN1
SCHEMBL4635459 0.77 CA12 (0.45) HPGDRECQLADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 CRHBP 3617/4885CRHR2 3179/4885KMT2A 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.